Inventor · disambiguated record
John Brian Mumm
Also filed as: MUMM JOHN · MUMM JOHN B · MUMM JOHN BRIAN
36 granted patents·22 pending applications·293 citations·filing 2004–2024
98Inventor score
Files withDEKA BIOSCIENCES INC31ARMO BIOSCIENCES INC13MERCK SHARP & DOHME4MEDIMMUNE LLC3LILLY CO ELI2
Top patents by PatentIndex Score
58 records- 0198US12145007B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Nov 19, 2024·4 cites·4 claims
- 0298US12121755B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 22, 2024·4 cites·4 claims
- 0398US12122814B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 22, 2024·4 cites·4 claims
- 0498US12116392B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 15, 2024·4 cites·4 claims
- 0598US12116390B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 15, 2024·4 cites·4 claims
- 0698US12116389B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 15, 2024·5 cites·4 claims
- 0798US12116391B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 15, 2024·4 cites·4 claims
- 0898US12116393B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 15, 2024·4 cites·6 claims
- 0998US12110317B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Oct 8, 2024·4 cites·4 claims
- 1098US12006346B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2023·Granted Jun 11, 2024·4 cites·4 claims
- 1198US11629178B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Apr 18, 2023·14 cites·6 claims
- 1298US11618775B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Apr 4, 2023·14 cites·6 claims
- 1398US11613563B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Mar 28, 2023·14 cites·6 claims
- 1498US11608368B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Mar 21, 2023·14 cites·4 claims
- 1598US11572397B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Feb 7, 2023·15 cites·6 claims
- 1698US11292822B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2021·Granted Apr 5, 2022·25 cites·6 claims
- 1798US10981965B2IL-10 variant molecules and methods of treating inflammatory diseaseDEKA BIOSCIENCES INC·Filed 2020·Granted Apr 20, 2021·25 cites·9 claims
- 1898US10981966B2IL-10 variant molecules conjugated with antibody variable domain regionsDEKA BIOSCIENCES INC·Filed 2020·Granted Apr 20, 2021·25 cites·13 claims
- 1998US10975133B2Methods for treating malignant tumors with IL-10 variant conjugatesDEKA BIOSCIENCES INC·Filed 2020·Granted Apr 13, 2021·22 cites·15 claims
- 2098US10975134B2Antibody-IL-10 fusion proteinsDEKA BIOSCIENCES INC·Filed 2020·Granted Apr 13, 2021·22 cites·10 claims
- 2198US10858412B2Antibody variable domain regions fused to IL-10 variant moleculesDEKA BIOSCIENCES INC·Filed 2020·Granted Dec 8, 2020·21 cites·11 claims
- 2294US2025135241A1Dual cytokine fusion proteins comprising il-10DEKA BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2390US9364517B2Method of treatment of lymphoma with pegylated IL-10MERCK SHARP & DOHME·Filed 2014·Granted Jun 14, 2016·14 cites·16 claims
- 2489US2024294591A1Il-10 variant molecules and methods for treating inflammatory disease and oncologyDEKA BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 2587US8865652B2Method of treating solid cancers with pegylated IL-10OFT MARTIN·Filed 2010·Granted Oct 21, 2014·14 cites·19 claims
- 2686US10195274B2Method of modulating a chimeric antigen receptor t cell immune response by administering IL-10ARMO BIOSCIENCES INC·Filed 2018·Granted Feb 5, 2019·4 cites·28 claims
- 2784US12268903B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Apr 8, 2025·0 cites·4 claims
- 2884US12263358B2Dual cytokine fusion proteins comprising IL-10DEKA BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·4 claims
- 2980US9833514B2Use of pegylated IL-10 to treat cancerMERCK SHARP & DOHME·Filed 2016·Granted Dec 5, 2017·2 cites·8 claims
- 3077US10398761B2Methods of using combinations of PEG-IL-10 and IL-15 for treating cancersARMO BIOSCIENCES INC·Filed 2016·Granted Sep 3, 2019·1 cites·20 claims
- 3177US2022106373A1Il-10 variant molecules and methods for treating inflammatory disease and oncologyDEKA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3276US10293043B2Methods of lowering serum cholesterolARMO BIOSCIENCES INC·Filed 2015·Granted May 21, 2019·2 cites·26 claims
- 3376US10010588B2Methods of using pegylated interleukin-10 for treating hyperlipidemiaARMO BIOSCIENCES INC·Filed 2014·Granted Jul 3, 2018·2 cites·15 claims
- 3476US2024409600A1Dual cytokine fusion proteins comprising multi-subunit cytokinesDEKA BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3574US10618970B2Method of treating cancer with IL-10 and antibodies that induce ADCCARMO BIOSCIENCES INC·Filed 2016·Granted Apr 14, 2020·1 cites·18 claims
- 3672US9823255B2Method for assessing protein identity and stabilityARMO BIOSCIENCES INC·Filed 2014·Granted Nov 21, 2017·1 cites·5 claims
- 3772US2023287075A1Dual cytokine fusion proteins comprising multi-subunit cytokinesDEKA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3872US2023340052A1Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereofDEKA BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3966US2019099487A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4065US2009214471A1Use of pegylated il-10 to treat cancerSCHERING CORP·Filed 2009·Application pending·0 cites
- 4164US2023210953A1Use of dual cytokine fusion proteins comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancerDEKA BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4263US10568968B2Methods for treatment of cancer with therapeutic combinations comprising PEG-IL-10MERCK SHARP & DOHME·Filed 2017·Granted Feb 25, 2020·0 cites·3 claims
- 4362US10209261B2Method for assessing protein identity and stabilityARMO BIOSCIENCES INC·Filed 2017·Granted Feb 19, 2019·0 cites·13 claims
- 4462US2008081031A1Use of Pegylated IL-10 to Treat CancerSCHERING CORP·Filed 2007·Application pending·0 cites
- 4561US2021214782A1Method of using genetic markers, single nucleotide polymorphisms and/or indels to determine responsiveness to il-10 or il-10 derivative treatmentDEKA BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4659US2016361415A1Methods of Using Interleukin-10 for Treating Diseases and DisordersARMO BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 4757US11413332B2Methods of using interleukin-10 for treating diseases and disordersLILLY CO ELI·Filed 2014·Granted Aug 16, 2022·0 cites·20 claims
- 4850US2018333464A1Methods of using interleukin-10 for treating diseases and disordersARMO BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 4949US2020199567A1Methods for selection and expansion of t cells expressing pd-1MEDIMMUNE LLC·Filed 2019·Application pending·0 cites
- 5049US2014212412A1Use of il-33 antagonists to treat fibrotic diseaseMERCK SHARP & DOHME·Filed 2013·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when John Brian Mumm files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →